Zhang et al., 2020)
"The 44% reduction in all-cause mortality observed among patients with obesity and co-occurring autoimmune disease is a striking finding that demands our attention, said Fatima Cody Stanford, M.D., M.P.H., M.P.A., M.B.A., FAHA and member of the American Heart Associations Lifestyle and Cardiometabolic Council
[DOI] [PMC free article] [PubMed] [Google Scholar] 95.Honka H, Koffert J, Hannukainen JC, Tuulari JJ, Karlsson HK, Immonen H, Oikonen V, Tolvanen T, Soinio M, Salminen P, Kudomi N, Mari A, Iozzo P, Nuutila P
Alternatives include other GLP-1 receptor agonists (such as semaglutide or liraglutide), SGLT2 inhibitors, optimised oral medications like metformin or DPP-4 inhibitors, or insulin therapy
altRx offers a modern approach to weight management with personalized GLP-1 injection therapies designed to support steady and results
In one clinical trial, 5 mg per week tirzepatide was slightly more effective than 1 mg per week semaglutide in reducing body weight and glycated hemoglobin (HbA1c)